Highlights
- Top Nifty 50 gainer: Sun Pharma rose 2.67% to close at ₹1,938.70 in the previous trading session.
- Fresh 52-week high: The stock touched ₹1,952, its highest level in the past one year.
- Strong FY26 performance: Revenue increased 11.9% YoY to ₹58,220.1 crore, while net profit rose 5% YoY to ₹11,479.4 crore.
- Innovative Medicines growth: Global Innovative Medicines sales reached US$1.42 billion during FY26, accounting for 20.7% of sales (excluding milestone income).
- Stock in focus today: Investors will monitor whether the stock sustains its breakout above previous highs after yesterday's rally.
Sun Pharmaceutical Industries Ltd. is expected to remain in focus when markets open today after the stock emerged as the top gainer in the Nifty 50 during the previous trading session. The pharmaceutical major gained 2.67%, closing at ₹1,938.70, after touching a fresh 52-week high of ₹1,952 on the NSE. The strong move reflected sustained buying interest in the stock and came amid broader strength in the pharmaceutical sector. Investors will now closely watch whether Sun Pharma can build on this momentum in today's session or witness profit booking near record levels.
Why Did Sun Pharma Rally in the Previous Session?
Sun Pharma's strong performance in the previous session reflected renewed investor interest in pharmaceutical stocks, with buying support pushing the stock to a new 52-week high. The stock opened at ₹1,889.90, moved to an intraday high of ₹1,952, touched a low of ₹1,888.20, and finally settled at ₹1,938.70, gaining ₹50.50 or 2.67% over the previous close.
The rally also extended the stock's ongoing uptrend, with Sun Pharma continuing to outperform several large-cap peers over recent weeks. The move indicates that investors remain optimistic about the company's long-term earnings profile and its growing contribution from higher-margin businesses.
Strong FY26 Performance Continues to Support Investor Confidence
Sun Pharma reported a healthy financial performance for FY26, driven by growth across its domestic formulations, emerging markets and innovative medicines businesses. According to the company's audited financial results, consolidated sales increased to ₹58,220.1 crore during FY26 from ₹52,026.6 crore in the previous year, representing 11.9% year-on-year growth. Consolidated EBITDA stood at ₹17,731.4 crore, while EBITDA margin improved to 30.3%. Net profit increased 5% year-on-year to ₹11,479.4 crore.
For the March quarter (Q4 FY26), the company reported consolidated sales of ₹14,559.8 crore, up 13.6% year-on-year, while net profit rose 26.2% to ₹2,714 crore. The Board also recommended a final dividend of ₹5 per equity share, in addition to the interim dividend of ₹11 per share already paid during FY26.
Innovative Medicines Business Remains a Key Growth Driver
Sun Pharma has steadily transformed its business from a predominantly generic drug manufacturer to a diversified pharmaceutical company with a strong focus on innovative and specialty medicines. During FY26, the company's Global Innovative Medicines business generated US$1.42 billion in sales and grew 16.4% over the previous year. The segment contributed 20.7% of total sales (excluding milestone income), highlighting its increasing importance in the company's revenue mix.
This strategy allows Sun Pharma to reduce its dependence on highly competitive generic markets while strengthening its presence in higher-margin therapeutic segments.
What Should Investors Watch Today?
With the stock closing near its record high, investors will closely monitor price action after the market opens. A sustained move above the previous session's high of ₹1,952 could indicate continued buying interest, while profit booking around higher levels may result in short-term consolidation.
Market participants are also likely to keep an eye on overall sentiment in the pharmaceutical sector, institutional activity and any company-specific developments that could influence trading during the session.
Technical Summary
From a technical perspective, Sun Pharma continues to display a strong bullish structure on the daily chart. The stock has been consistently forming higher highs and higher lows, indicating that buyers remain in control of the trend. Yesterday's strong bullish candle, accompanied by healthy trading volume, reinforces the positive momentum.
The immediate resistance is placed around ₹1,952, which is also the stock's recent 52-week high. A decisive close above this level could pave the way for further upside. On the downside, the ₹1,900–₹1,910 zone is expected to provide the first layer of support, while a stronger support zone is visible around ₹1,860 based on recent swing lows. Although the overall trend remains positive, traders should also be prepared for short-term consolidation after the sharp rally.
Source: TradingView
Outlook
Sun Pharma enters the new trading session with positive momentum backed by healthy financial performance, continued expansion of its Innovative Medicines business and sustained investor interest. While the stock has already delivered a strong rally, its movement today will depend on whether buyers are able to sustain momentum above yesterday's breakout levels. Investors may continue to track the stock closely as one of the key large-cap pharmaceutical names in the current market environment.
FAQs
Q: Why is Sun Pharma in focus today?
A: Sun Pharma is in focus after emerging as the top gainer in the Nifty 50 during the previous trading session, gaining 2.67% and touching a fresh 52-week high.
Q: What was Sun Pharma's FY26 revenue?
A: Sun Pharma reported consolidated revenue of ₹58,220.1 crore in FY26, an increase of 11.9% year-on-year.
Q: What was Sun Pharma's FY26 net profit?
A: The company reported a consolidated net profit of ₹11,479.4 crore for FY26.
Q: What are the key levels to watch?
A: The immediate resistance is around ₹1,952, while ₹1,900–₹1,910 is the first important support zone based on the recent price structure.